| CA: Schedule II
DE: Anlage II (Prohibited)
US: Schedule I
Illegal in China|
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication, but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA which had not previously been reported.
AB-FUBINACA has been linked to hospitalizations and deaths due to its use.
In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.
AB-FUBINACA is an Anlage II controlled substance in Germany as of November 2014.
As of October 2015 AB-FUBINACA is a controlled substance in China.